SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: zeta1961 who wrote (1565)5/3/2005 12:45:03 PM
From: Jim Oravetz  Read Replies (1) of 1826
 
MGI Pharma by Baird Research (22.71, April 26)

Maintain Outperform/Higher Risk rating, 35 price target. Following an investor call we hosted [April 25] with chief financial officer CFO Jim Hawley, we feel increasingly comfortable that recently raised DSO [days sales outstanding] concerns are overblown, and that MOGN's quality of earnings is high. Given the stock's selloff, primarily-we believe-on this concern, but in the face of March's Aloxi [which treats chemotherapy side-effects] script number, we are aggressive buyers…As outlined in footnotes of MOGN's 10-K, administrative fees are included in accounts receivables, but have been removed from reported revenue, so a more apples-to-apples view of DSO might back this number out of accounts-receivables…We generally see little to be concerned about. Rather, we would focus on Aloxi's trajectory, which continues to be strong.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News